Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

CD Bioparticles announces its custom synthesis services of Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles (MNPs).

(PRUnderground) June 21st, 2025

With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the expansion of its custom services to include the synthesis of Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles (MNPs). These customized magnetic particles can be conjugated with the biologically targeted small molecules desired by researchers, and have a uniform size and shape, as well as an appropriate conjugation density.

Research on molecular targeted therapy for tumors is increasing, and new targeted therapeutic agents are emerging. Some small molecules can be used as novel therapeutic agents. Combined with nanotechnology, “smart” drugs can actively target tumors by binding to corresponding receptors on tumor cells through interactions with phenotype-specific ligands conjugated to the delivery vehicle. Additionally, binding to certain receptors can trigger internalization and help avoid the development of resistance mechanisms.

The rationale behind targeting via small molecules is to affect the molecular biology underlying tumorigenesis by modulating the activity of protein targets. These targets mainly include enzymes and receptors. Small molecules acting on receptors can be classified as agonists or antagonists. Small molecules that act as enzyme inhibitors reduce their catalytic activity by binding to them.

These molecules can bind to targets highly expressed on cancer cell surfaces and be targeted during drug delivery. For example, folic acid (folates) can be used. Cancer and embryonic cells preferentially use the folate receptor (FR), which has a high affinity for folic acid (K_d = 1–10nM) and can uptake folic acid via receptor-mediated endocytosis. This makes folic acid an attractive ligand for active targeting.

Another available option is the prostate-specific membrane antigen (PSMA) inhibitor EC1169. PSMA is a surface glycoprotein associated with high-grade and metastatic prostate cancer. It undergoes rapid internalization upon binding to mAbs or other ligands. Additionally, there is the glucose transporter targeting agent glufosfamide (D-19575). Cancer cells depend heavily on glucose and glycolysis for survival and express glucose transporters.

To support researchers to develop highly precise drug delivery systems, CD Bioparticles now offers various custom services for bio-targeted small molecules conjugated magnetic nanoparticles, including the synthesis of basic magnetic particles, the functionalization and conjugation of custom small molecules, and basic characterization. These particles possess several key properties, including active targeting, easy internalization, reduced drug resistance, and an enhanced permeability and retention (EPR) effect. In addition, they can be applied in diverse fields, such as biological imaging, biosensing, chemotherapy drug delivery, and synergy with other therapies like magnetic hyperthermia.

Clients can specify requirements for particle diameter, component, functionalization type and density, desired bio-targeted small molecule, quantity, format, and QC materials. For more information on CD Bioparticles’ custom Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles synthesis services, please visit https://www.cd-bioparticles.com/services/bio-targeted-small-molecules-conjugated-magnetic-nanoparticles.html.

About CD Bioparticles

CD Bioparticles specializes in manufacturing and supplying nanoparticles, microparticles, and coatings for diagnostics and research, alongside developing customized, biocompatible drug delivery systems. We offer diverse formulation technologies (from liposomes to polymer nanoparticles) and comprehensive services, including surface functionalization, antibody immobilization, and contract research for drug delivery.

The post CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy first appeared on

Press Contact

Name: Richard J. Gray
Phone: 1-631-346-0027
Email: Contact Us

Original Press Release.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.